Internal Reference Number: FOI_8442
Date Request Received: 07/02/2025 00:00:00
Date Request Replied To: 26/02/2025 00:00:00
This response was sent via: By Email
Request Summary: Oncology Breast Cancer
Request Category: Researcher
| Question Number 1: How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies: • Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) • Abemaciclib + Fulvestrant • Alpelisib + Fulvestrant • Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide • Aromatase Inhibitor as a single agent • Atezolizumab • Capecitabine as a single agent • Carboplatin + Paclitaxel • Elacestrant • Eribulin as a single agent or in combination • Everolimus + Exemestane • Fulvestrant as a single agent • Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) • Palbociclib + Fulvestrant • Parp Inhibitors (Olaparib/Talazoparib) • Pembrolizumab • Pertuzumab (Perteja) + Trastuzumab (Herceptin) • Phesgo (Pertuzumab + Trastuzumab in a single injection) • Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) • Ribociclib + Fulvestrant • Sacituzumab Govitecan • Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent • Trastuzumab deruxtecan (Enhertu) • Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel • Trastuzumab emtansine (Kadcyla) • Any other active systemic anti-cancer therapy | |
| Answer To Question 1: • Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) 22 • Abemaciclib + Fulvestrant 5 • Alpelisib + Fulvestrant <5 • Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide 6 • Aromatase Inhibitor as a single agent - unable to answer • Atezolizumab 0 • Capecitabine as a single agent 12 • Carboplatin + Paclitaxel <5 • Elacestrant 0 • Eribulin as a single agent or in combination 0 • Everolimus + Exemestane 0 • Fulvestrant as a single agent unable to answer • Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) 25 • Palbociclib + Fulvestrant <5 • Parp Inhibitors (Olaparib/Talazoparib) 0 • Pembrolizumab 5 • Pertuzumab (Perteja) + Trastuzumab (Herceptin) <5 • Phesgo (Pertuzumab + Trastuzumab in a single injection) 20 • Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) 14 • Ribociclib + Fulvestrant <5 • Sacituzumab Govitecan 5 • Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent 6 • Trastuzumab deruxtecan (Enhertu) 5 • Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel 13 • Trastuzumab emtansine (Kadcyla) <5 • Any other active systemic anti-cancer therapy 25 | |
| Question Number 2: How many patients have been treated for metastatic breast cancer in the past 3 months with the following systemic anti-cancer therapies: • Phesgo (Pertuzumab + Trastuzumab in a single injection) • Pertuzumab (Perteja) + Trastuzumab (Herceptin) • Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel • Trastuzumab deruxtecan (Enhertu) • Trastuzumab emtansine (Kadcyla) | |
| Answer To Question 2: • Phesgo (Pertuzumab + Trastuzumab in a single injection) 16 • Pertuzumab (Perteja) + Trastuzumab (Herceptin) <5 • Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel 6 • Trastuzumab deruxtecan (Enhertu) 5 • Trastuzumab emtansine (Kadcyla) 0 | |
| Question Number 3: If breast cancer is not treated at or within the Trust, where are patients referred ? | |
| Answer To Question 3: N/A | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of ¾¨Ó㴫ý Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
